Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II

Zhipeng Meng, Tao Li, Xiaoxiao Ma, Xiaoqiong Wang, Carl Van Ness, Yichao Gan, Hong Zhou, Jinfen Tang, Guiyu Lou, Yafan Wang, Jun Wu, Yun Yen, Rongzhen Xu, Wendong Huang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer and improve the prognosis of this disease. Here, we report that berbamine and one of its derivatives, bbd24, potently suppressed liver cancer cell proliferation and induced cancer cell death by targeting Ca2+ /calmodulin-dependent protein kinase II (CAMKII). Furthermore, berbamine inhibited the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice and downregulated the self-renewal abilities of liver cancer-initiating cells. Chemical inhibition or short hairpin RNA-mediated knockdown of CAMKII recapitulated the effects of berbamine, whereas overexpression of CAMKII promoted cancer cell proliferation and increased the resistance of liver cancer cells to berbamine treatments. Western blot analyses of human liver cancer specimens showed that CAMKII was hyperphosphorylated in liver tumors compared with the paired peritumor tissues, which supports a role of CAMKII in promoting human liver cancer progression and the potential clinical use of berbamine for liver cancer therapies. Our data suggest that berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.

Original languageEnglish
Pages (from-to)2067-2077
Number of pages11
JournalMolecular Cancer Therapeutics
Volume12
Issue number10
DOIs
Publication statusPublished - Oct 1 2013
Externally publishedYes

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinase Type 2
Liver Neoplasms
Growth
Neoplasms
berbamine
Cell Proliferation
Inbred NOD Mouse
SCID Mice
Small Interfering RNA
Cause of Death
Cell Death
Down-Regulation
Western Blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II. / Meng, Zhipeng; Li, Tao; Ma, Xiaoxiao; Wang, Xiaoqiong; Ness, Carl Van; Gan, Yichao; Zhou, Hong; Tang, Jinfen; Lou, Guiyu; Wang, Yafan; Wu, Jun; Yen, Yun; Xu, Rongzhen; Huang, Wendong.

In: Molecular Cancer Therapeutics, Vol. 12, No. 10, 01.10.2013, p. 2067-2077.

Research output: Contribution to journalArticle

Meng, Z, Li, T, Ma, X, Wang, X, Ness, CV, Gan, Y, Zhou, H, Tang, J, Lou, G, Wang, Y, Wu, J, Yen, Y, Xu, R & Huang, W 2013, 'Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II', Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2067-2077. https://doi.org/10.1158/1535-7163.MCT-13-0314
Meng, Zhipeng ; Li, Tao ; Ma, Xiaoxiao ; Wang, Xiaoqiong ; Ness, Carl Van ; Gan, Yichao ; Zhou, Hong ; Tang, Jinfen ; Lou, Guiyu ; Wang, Yafan ; Wu, Jun ; Yen, Yun ; Xu, Rongzhen ; Huang, Wendong. / Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II. In: Molecular Cancer Therapeutics. 2013 ; Vol. 12, No. 10. pp. 2067-2077.
@article{6787183bbac041a0bcda3cbff928b592,
title = "Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II",
abstract = "Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer and improve the prognosis of this disease. Here, we report that berbamine and one of its derivatives, bbd24, potently suppressed liver cancer cell proliferation and induced cancer cell death by targeting Ca2+ /calmodulin-dependent protein kinase II (CAMKII). Furthermore, berbamine inhibited the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice and downregulated the self-renewal abilities of liver cancer-initiating cells. Chemical inhibition or short hairpin RNA-mediated knockdown of CAMKII recapitulated the effects of berbamine, whereas overexpression of CAMKII promoted cancer cell proliferation and increased the resistance of liver cancer cells to berbamine treatments. Western blot analyses of human liver cancer specimens showed that CAMKII was hyperphosphorylated in liver tumors compared with the paired peritumor tissues, which supports a role of CAMKII in promoting human liver cancer progression and the potential clinical use of berbamine for liver cancer therapies. Our data suggest that berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.",
author = "Zhipeng Meng and Tao Li and Xiaoxiao Ma and Xiaoqiong Wang and Ness, {Carl Van} and Yichao Gan and Hong Zhou and Jinfen Tang and Guiyu Lou and Yafan Wang and Jun Wu and Yun Yen and Rongzhen Xu and Wendong Huang",
year = "2013",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-13-0314",
language = "English",
volume = "12",
pages = "2067--2077",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II

AU - Meng, Zhipeng

AU - Li, Tao

AU - Ma, Xiaoxiao

AU - Wang, Xiaoqiong

AU - Ness, Carl Van

AU - Gan, Yichao

AU - Zhou, Hong

AU - Tang, Jinfen

AU - Lou, Guiyu

AU - Wang, Yafan

AU - Wu, Jun

AU - Yen, Yun

AU - Xu, Rongzhen

AU - Huang, Wendong

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer and improve the prognosis of this disease. Here, we report that berbamine and one of its derivatives, bbd24, potently suppressed liver cancer cell proliferation and induced cancer cell death by targeting Ca2+ /calmodulin-dependent protein kinase II (CAMKII). Furthermore, berbamine inhibited the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice and downregulated the self-renewal abilities of liver cancer-initiating cells. Chemical inhibition or short hairpin RNA-mediated knockdown of CAMKII recapitulated the effects of berbamine, whereas overexpression of CAMKII promoted cancer cell proliferation and increased the resistance of liver cancer cells to berbamine treatments. Western blot analyses of human liver cancer specimens showed that CAMKII was hyperphosphorylated in liver tumors compared with the paired peritumor tissues, which supports a role of CAMKII in promoting human liver cancer progression and the potential clinical use of berbamine for liver cancer therapies. Our data suggest that berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.

AB - Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer and improve the prognosis of this disease. Here, we report that berbamine and one of its derivatives, bbd24, potently suppressed liver cancer cell proliferation and induced cancer cell death by targeting Ca2+ /calmodulin-dependent protein kinase II (CAMKII). Furthermore, berbamine inhibited the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice and downregulated the self-renewal abilities of liver cancer-initiating cells. Chemical inhibition or short hairpin RNA-mediated knockdown of CAMKII recapitulated the effects of berbamine, whereas overexpression of CAMKII promoted cancer cell proliferation and increased the resistance of liver cancer cells to berbamine treatments. Western blot analyses of human liver cancer specimens showed that CAMKII was hyperphosphorylated in liver tumors compared with the paired peritumor tissues, which supports a role of CAMKII in promoting human liver cancer progression and the potential clinical use of berbamine for liver cancer therapies. Our data suggest that berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.

UR - http://www.scopus.com/inward/record.url?scp=84885624465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885624465&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0314

DO - 10.1158/1535-7163.MCT-13-0314

M3 - Article

VL - 12

SP - 2067

EP - 2077

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -